LINC01090: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01090

NCBI ID: G104355152

LINC01090

Other Name(s): long intergenic non-protein coding RNA 1090 | Long intergenic non-protein coding RNA 1090

LINC01090: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC01090 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature of being located between the 5' and 3' ends of exons, which is known as a intron . This unique property makes LINC01090 different from other lncRNAs. LINC01090 has also been shown to play a role in various cellular processes, including gene regulation, cell signaling, and tissue development.

Drug Target Potential

The potential drug targets for LINC01090 are numerous. One of the main targets is the regulation of gene expression. LINC01090 has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences. This binding can either enhance or suppress gene expression, depending on the context. For example, LINC01090 has been shown to enhance the expression of the gene involved in the development of cancer. On the other hand, LINC01090 can also suppress the expression of genes involved in cell signaling pathways, such as the NF-kappa pathway.

Another potential drug target for LINC01090 is the regulation of cell signaling pathways is the PI3K/Akt signaling pathway. This pathway is involved in various cellular processes, including cell survival, angiogenesis, and inflammation. LINC01090 has been shown to play a role in the regulation of this pathway by binding to the protein kinase Akt. This binding can either enhance or suppress the activity of Akt, depending on the context.

In addition to its role in gene expression and signaling pathways, LINC01090 has also been shown to be involved in the regulation of tissue development and cell differentiation. For example, LINC01090 has been shown to play a role in the regulation of the specification of stem cells. into different cell types.

Biomarker Potential

The potential use of LINC01090 as a biomarker is also significant. LINC01090 has been shown to play a role in the regulation of various cellular processes, including cell signaling pathways and tissue development. This makes it a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the main advantages of using LINC01090 as a biomarker is its ability to be easily detected and quantified. This is because LINC01090 is a RNA molecule, which is typically more stable and easier to detect than protein molecules. This makes it easier to measure the levels of LINC01090 in the body, which can be used to assess the effectiveness of a drug or to diagnose a disease.

Another advantage of LINC01090 as a biomarker is its ability to be targeted specifically. This is because LINC01090 is a non-protein molecule, which means it is not involved in the production of proteins that can interact with other molecules. This allows researchers to focus on studying the effects of a drug or other molecules on LINC01090, rather than on studying the interactions between different molecules.

Conclusion

In conclusion, LINC01090 is a long intergenic non-protein-coding RNA that has a unique feature of being located between the 5' and 3' ends of exons. It has been shown to play a role in various cellular processes, including gene expression, cell signaling, and tissue development. As a result, LINC01090 is a potential drug target and biomarker for various diseases. Further research is needed to fully understand the effects of LINC01090 on cellular processes and its potential as a drug.

Protein Name: Long Intergenic Non-protein Coding RNA 1090

The "LINC01090 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01090 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets